Production (Stage)
Werewolf Therapeutics, Inc.
HOWL
$1.19
$0.1110.19%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.33% | -22.35% | 3.34% | -6.52% | -34.91% |
| Total Depreciation and Amortization | -3.62% | -2.64% | 0.00% | -2.16% | 0.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.42% | 5.10% | 24.59% | -26.83% | 19.12% |
| Change in Net Operating Assets | -224.57% | 148.09% | 108.66% | 125.16% | -150.56% |
| Cash from Operations | -32.95% | -14.36% | 12.10% | 7.32% | -233.63% |
| Capital Expenditure | -- | -4,000.00% | 82.35% | 84.68% | 43.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -4,000.00% | 82.35% | 84.68% | 43.94% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -95.30% | 123.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | -- | 42,550.00% | 99.94% | -147.98% | 123.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -60.20% | 5.16% | 47.85% | -592.97% | 13.08% |